Cancan Diagnostic is thrilled to unveil K9-LiquiDX, the world’s inaugural Minimal Residual Disease (MRD) test tailored for dogs, heralding a new chapter in veterinary cancer management. Launching on March 5, 2024, this pioneering test offers a novel approach for veterinarians and dog owners to detect early signs of cancer relapse and monitor the disease with unprecedented precision. K9-LiquiDX stands out by detecting minuscule remnants of cancer cells post-treatment, which conventional methods might overlook, thus promising to transform cancer care for our canine friends.
Crafted by a team of eminent researchers and veterinary cancer specialists, K9-LiquiDX employs cutting-edge molecular diagnostic techniques to spot the slightest indications of cancer recurrence. Its high sensitivity makes it an invaluable asset for early intervention and customised treatment plans, signifying a major advancement in monitoring treatment efficacy and modifying approaches to better serve our pets.
Key Advantages of K9-LiquiDX include:
- Early Relapse Detection: Offers veterinarians the capability to identify cancer relapse at its nascent stage, potentially before the appearance of clinical signs.
- Precision Cancer Monitoring: Delivers comprehensive insights into the cancer’s progression and treatment response, facilitating more tailored and effective management.
- Enhanced Treatment Strategies: Aids in making well-informed treatment modifications, which may lead to improved outcomes and life quality for canine cancer patients.
Dr. Maciej Parys, CEO of Cancan Diagnostic, highlighted the significance of this innovation, saying, “K9-LiquiDX is more than just a diagnostic test; it has a potential to revolutionise how we monitor dogs with cancer and help them and their families through improvement of their quality of life. By focusing on early relapse detection and precision monitoring, we’re opening new pathways for personalised cancer care in veterinary medicine. This test is a testament to our commitment to pioneering advancements that make a real difference in the lives of pets and their owners.”
From March 5, 2024, K9-LiquiDX will be accessible to veterinary clinics throughout the UK, with Cancan Diagnostic providing comprehensive support and resources to ensure seamless integration of this test into existing cancer treatment protocols.
Since its establishment in 2022, Cancan Diagnostic has been a trailblazer in veterinary diagnostic innovations, aiming to elevate pet healthcare by integrating the latest scientific breakthroughs and technologies into veterinary practice. The introduction of K9-LiquiDX reaffirms the company’s dedication to leading the field of veterinary oncology and improving the wellbeing of pets globally.
